WO2024019171A1 - Composition destinée à améliorer le débit sanguin oculaire - Google Patents
Composition destinée à améliorer le débit sanguin oculaire Download PDFInfo
- Publication number
- WO2024019171A1 WO2024019171A1 PCT/JP2023/026874 JP2023026874W WO2024019171A1 WO 2024019171 A1 WO2024019171 A1 WO 2024019171A1 JP 2023026874 W JP2023026874 W JP 2023026874W WO 2024019171 A1 WO2024019171 A1 WO 2024019171A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ginger
- blood flow
- extract
- ocular
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 105
- 230000004386 ocular blood flow Effects 0.000 title claims abstract description 73
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 110
- 235000008397 ginger Nutrition 0.000 claims abstract description 110
- 239000000284 extract Substances 0.000 claims abstract description 61
- 230000036541 health Effects 0.000 claims abstract description 26
- 230000004087 circulation Effects 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 230000002792 vascular Effects 0.000 claims abstract description 24
- 206010047555 Visual field defect Diseases 0.000 claims abstract description 14
- 230000000007 visual effect Effects 0.000 claims abstract description 13
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 12
- 241000234314 Zingiber Species 0.000 claims description 106
- 230000017531 blood circulation Effects 0.000 claims description 57
- 241000583531 Alpinia purpurata Species 0.000 claims description 36
- 235000013305 food Nutrition 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 18
- 206010039729 Scotoma Diseases 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 12
- 208000010412 Glaucoma Diseases 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 235000009508 confectionery Nutrition 0.000 claims description 8
- 239000007910 chewable tablet Substances 0.000 claims description 7
- 239000006191 orally-disintegrating tablet Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 230000002207 retinal effect Effects 0.000 claims description 7
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 5
- 229940068682 chewable tablet Drugs 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 5
- 201000004569 Blindness Diseases 0.000 claims description 4
- 206010048964 Carotid artery occlusion Diseases 0.000 claims description 4
- 201000007527 Retinal artery occlusion Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 206010001902 amaurosis Diseases 0.000 claims description 4
- 210000004004 carotid artery internal Anatomy 0.000 claims description 4
- 230000001052 transient effect Effects 0.000 claims description 4
- 208000028867 ischemia Diseases 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 20
- 244000273928 Zingiber officinale Species 0.000 abstract description 4
- 239000001841 zingiber officinale Substances 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 60
- 238000000034 method Methods 0.000 description 54
- 238000012360 testing method Methods 0.000 description 44
- 235000020708 ginger extract Nutrition 0.000 description 39
- 229940002508 ginger extract Drugs 0.000 description 37
- 210000001519 tissue Anatomy 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 102100033902 Endothelin-1 Human genes 0.000 description 25
- 101800004490 Endothelin-1 Proteins 0.000 description 25
- 210000004204 blood vessel Anatomy 0.000 description 19
- 230000037396 body weight Effects 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- 239000002775 capsule Substances 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000306 component Substances 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 238000005469 granulation Methods 0.000 description 8
- 230000003179 granulation Effects 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 7
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000209094 Oryza Species 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- XFZJEEAOWLFHDH-NFJBMHMQSA-N procyanidin B2 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-NFJBMHMQSA-N 0.000 description 6
- NLDDIKRKFXEWBK-CQSZACIVSA-N (S)-6-Gingerol Natural products CCCCC[C@@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-CQSZACIVSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 5
- LVCXAKWFQYYXLU-UHFFFAOYSA-N <6>-shogaol Natural products CCCCC=CCC(=O)CCc1ccc(O)c(OC)c1 LVCXAKWFQYYXLU-UHFFFAOYSA-N 0.000 description 4
- VBKDALTZEUBYTQ-RBMCBPMHSA-N Dehydrogingerdione Chemical compound COc1cc(\C=C\C(\O)=C/C(C)=O)ccc1O VBKDALTZEUBYTQ-RBMCBPMHSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000001043 capillary endothelial cell Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004410 intraocular pressure Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 235000021251 pulses Nutrition 0.000 description 4
- 229920001864 tannin Polymers 0.000 description 4
- 235000018553 tannin Nutrition 0.000 description 4
- 239000001648 tannin Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229920002350 Procyanidin B2 Polymers 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 210000001927 retinal artery Anatomy 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010058558 Hypoperfusion Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 241000234299 Zingiberaceae Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 210000003287 ciliary artery Anatomy 0.000 description 2
- 230000008645 cold stress Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000002780 gingerol Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000001636 ophthalmic artery Anatomy 0.000 description 2
- 210000003733 optic disk Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001562081 Ikeda Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000227425 Pieris rapae crucivora Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 241000963384 Zingiber mioga Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- -1 etc. can be used Polymers 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004895 regional blood flow Effects 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 238000010153 Šidák test Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a composition for improving ocular blood flow.
- compositions for improving and/or maintaining ocular blood flow compositions for maintaining the health of vascular tissue in the eye, anti-aging compositions for the eye, health of the eye, visual field narrowing, visual field defects. , or compositions for improving and/or maintaining the appearance or expansion of scotoma, and compositions for treating and/or preventing ocular circulation disorders.
- Ginger contains gingerol as a main component, and also contains shogaol, dehydrogingerdione, etc. Ginger is known to have various effects due to these components, and its use has been proposed for improving indigestion, motion sickness, diabetes treatment, analgesic, etc. (Patent Document 1).
- the present invention aims to evaluate the effect on ocular blood flow when ginger is used in the eye region, and to provide a composition that improves conditions related to ocular blood flow.
- the present inventors conducted intensive studies and found that ginger and/or its extracts, which are safely used in the food and pharmaceutical fields, are effective in improving and/or maintaining ocular blood flow.
- the present inventors have discovered that the compound has activity, etc., and have completed the present invention.
- the present invention provides the following compositions.
- a composition for improving and/or maintaining ocular blood flow containing ginger and/or an extract thereof.
- a composition for maintaining the health of vascular tissue in the eye containing ginger and/or an extract thereof.
- a composition for treating and/or preventing ocular circulation disorders containing ginger and/or an extract thereof.
- the ocular circulation disorder is glaucoma, retinal vein occlusion, retinal artery occlusion, ocular ischemic syndrome, internal carotid artery occlusion, renal retinopathy, transient amaurosis, or age-related macular degeneration [5 The composition described in ].
- composition according to [8] which is an orally disintegrating tablet, a chewable tablet, a candy, a granule, a powder, or a liquid.
- Ginger and/or its extract is red ginger and/or its extract, The composition according to any one of [1] to [8].
- composition according to [1] wherein the ocular blood flow is retinal and/or choroidal blood flow.
- FIG. 1 is a graph showing the measurement results of blood flow in ocular blood vessels due to ginger administration in Test Example 2.
- FIG. 2 is a photograph of the posterior segment of the eye showing the results of an examination of the ocular blood flow reduction type model in Test Example 3.
- FIG. 3 is a graph showing the study results of the ocular blood flow reduction type model in Test Example 3.
- FIG. 4 is a photograph of the posterior segment of the eye 10 minutes after endothelin-1 administration in Test Example 3, in which the influence of ginger administration was evaluated.
- FIG. 5 is a graph showing the measurement results of blood flow in ocular blood vessels due to ginger administration 10 minutes after endothelin-1 administration in Test Example 3.
- FIG. 1 is a graph showing the measurement results of blood flow in ocular blood vessels due to ginger administration in Test Example 2.
- FIG. 2 is a photograph of the posterior segment of the eye showing the results of an examination of the ocular blood flow reduction type model in Test Example 3.
- FIG. 3 is a graph showing the study results of the o
- FIG. 6 is a graph showing the measurement results of blood flow in ocular blood vessels due to ginger administration 10 minutes after endothelin-1 administration in Test Example 3.
- FIG. 7 is a graph showing the measurement results of blood flow in ocular blood vessels due to ginger administration 10 minutes after endothelin-1 administration in Test Example 3.
- FIG. 8 is a photograph of the posterior segment of the eye 20 minutes after endothelin-1 administration in Test Example 3, in which the influence of ginger administration was evaluated.
- FIG. 9 is a graph showing the measurement results of blood flow in ocular blood vessels due to ginger administration 20 minutes after endothelin-1 administration in Test Example 3.
- FIG. 10 is a graph showing the measurement results of blood flow in ocular blood vessels due to ginger administration 20 minutes after endothelin-1 administration in Test Example 3.
- FIG. 10 is a graph showing the measurement results of blood flow in ocular blood vessels due to ginger administration 20 minutes after endothelin-1 administration in Test Example 3.
- FIG. 11 is a graph showing the measurement results of blood flow in ocular blood vessels due to ginger administration 20 minutes after endothelin-1 administration in Test Example 3.
- FIG. 12 is a graph showing the measurement results of the blood flow rate of the eye blood vessels due to ginger administration after cold loading in Test Example 4.
- composition for improving and/or maintaining ocular blood flow of the present invention contains ginger and/or an extract thereof.
- Zingiber officinale is a perennial herbaceous plant belonging to the Zingiberaceae family. Ginger is known for its warming effects on the body, and has been consumed in countries around the world since ancient times. Ginger contains gingerol as a main component, and trace amounts of shogaol, dehydrogingerdione, and the like. Furthermore, ginger also contains trace amounts of more than 50 kinds of volatile fragrance oil components and more than 200 kinds of pungent components, and these main components and trace components bring about various physiological activities and improve lipid metabolism and arteries. Research is underway in the fields of sclerosis, cancer, allergies, arthritis, etc.
- the part of ginger is not particularly limited as long as it achieves the effects of the present invention, but examples include at least one part selected from the group consisting of roots, stems, leaves, and flowers; , at least one selected from the group consisting of leaves, more preferably at least one selected from the group consisting of roots and stems, and even more preferably rhizomes.
- the effects can be achieved using ginger and/or its extract.
- the extraction method is not limited as long as the effects of the present invention are achieved.
- ginger extract refers to the whole plant or the necessary parts of the plant (flowers, flower heads, flower buds, buds, spikes, leaves, branches, foliage, rhizomes, rhizomes, roots, bark, fruits). , pericarp, legumes, seeds, etc., preferably rhizomes), it may be used as it is, it may be further purified, it may be concentrated, it may be obtained by synthesis. , commercially available products can also be used.
- the method for obtaining the plant extract is not particularly limited, and conventional extraction methods, purification methods, concentration methods, synthesis methods, dry powderization methods, etc. are employed.
- the ginger extract is an extract obtained by immersion extraction of ginger or its pulverized product with water and/or an organic solvent and filtering the residue, an extract obtained by removing the solvent from this extract, Alternatively, it refers to these fine powders, or those obtained by dissolving, dispersing, or diluting the above-mentioned extract or solvent-removed product using an appropriate solvent, and it is also possible to use commercially available products.
- the ginger extract can also be extracted after processing the ginger rhizome, such as steaming it. Further, the periderm of the rhizome may be removed, or it may be used as it is without removing it.
- the extraction solvent includes water (including hot water), methanol, ethanol, isopropanol, ethylene glycol, 1,3- Alcohols such as butylene glycol and glycerin, esters such as ethyl acetate, ketones such as acetone and methyl ethyl ketone, nitriles such as acetonitrile, ethers such as diethyl ether and tetrahydrofuran, saturated substances such as pentane, hexane, cyclopentane, and cyclohexane.
- water including hot water
- methanol ethanol
- isopropanol ethylene glycol
- 1,3- Alcohols such as butylene glycol and glycerin
- esters such as ethyl acetate, ketones such as acetone and methyl ethyl ketone
- nitriles such as acetonitrile
- ethers such as diethyl ether and
- Hydrocarbons aromatic hydrocarbons such as toluene, halogenated hydrocarbons such as dichloromethane and chloroform, and other organic solvents such as dimethylformamide and dimethyl sulfoxide (all of which may contain water) can be used as appropriate. , or a mixture of two of them may be used. Among these solvents, water, ethanol, 1,3-butylene glycol, or a mixed solution thereof is preferred.
- the extracts described herein can be obtained from various raw material companies, and are typically sold in a form that includes, but is not limited to, excipients.
- the amount of extract refers to the dry solid content.
- the extraction solvent for the ginger extract is not limited as long as it achieves the effects of the present invention, but water, ethanol, or aqueous ethanol is preferable, and aqueous ethanol is more preferable.
- ginger extract powder Matsuura Pharmaceutical Co., Ltd.
- ginger extract NE Ikeda Tokako Co., Ltd.
- red ginger extract P Oryza Yuka Co., Ltd.
- Co., Ltd. and Kintoki Ginger Powder (Koei Kogyo Co., Ltd.), but are not limited to these.
- Ginger is also used as a herbal medicine in Chinese herbal preparations, and raw ginger is called ginger, dried raw ginger is called dried ginger, and steamed and dried ginger is called dried ginger. It is distinguished from (kankyo). Ginger in crude drugs is defined in the 18th edition of the Japanese Pharmacopoeia, and when it is quantified, it is [6]-gingerol (C 17 H 26 O 4 :294. 39) in an amount of 0.3% or more. Herbal medicines that meet the standards set by the Japanese Pharmacopoeia are commercially available, and such herbal medicines may be used in the present invention.
- Red ginger Zingiber officinale Rubra.
- Red ginger has a stronger spiciness than common white ginger, and is used as a spice and traditional medicine.
- red ginger or red ginger extracts include, for example, red ginger powder (Ryusendo), Hokka Hokka red ginger powder (M&K Laboratories), red ginger extract P, and red ginger extract-WSP. , Red Ginger Extract-PC, Red Ginger Extract-WSPC, Red Ginger Extract-LC (all manufactured by Oryza Yuka Co., Ltd.), but are not limited to these.
- the red ginger extract preferably contains 3.0% by mass or more of [6]-gingerol and [6]-shogaol, and preferably contains 6.0% by mass or more. More preferred. Further, it is preferable that the tannin content is 0.5% by mass or more in terms of procyanidin B2, and more preferably 1.5% by mass or more. Further, although not limited to, the excipient preferably contains cyclodextrin in an amount of 10% to 90%, more preferably 30% to 70% by weight, even more preferably 33% to 67% by weight. .
- the content is, for example, 0.01% by mass or more, 0.05% by mass or more, 0.1% by mass based on the total amount of the composition. % or more, 0.3% by mass or more, 0.5 mass% or more, 1 mass% or more, 3 mass% or more, 5 mass% or more, 10 mass% or more, 20 mass% or more, and 90 mass% Below, the content may be 50% by mass or less, 25% by mass or less, 10% by mass or less, 5% by mass or less, 3% by mass or less, or 1% by mass or less.
- the content of ginger extract is preferably 0.01 to 95% by mass, more preferably 0.05 to 70% by mass, even more preferably 0.1 to 50% by mass, particularly preferably 0. .5 to 30% by mass.
- the content of ginger when using ginger, its content may be, for example, 0.1% by mass or more, 0.5% by mass or more, 1% by mass or more, 3% by mass or more based on the total amount of the composition. % mass% or more, 5 mass% or more, 10 mass% or more, 30 mass% or more, 50 mass% or more, and 99 mass% or less, 95 mass% or less, 90 mass% or less, 80 mass% or less, 70 mass% or more It may be less than 60% by mass, or less than 60% by mass.
- the content of ginger is preferably 0.1 to 99% by mass, more preferably 0.5 to 95% by mass, even more preferably 1 to 90% by mass, and particularly preferably 3 to 80% by mass. It is.
- the ratio of the herbal medicine is not limited, but for example, 1 to 100:1, 10 to 80:1, more preferably 20 to 60:1, even more preferably 30 to 45:1 (for example, 30 to 45:1). 1 kg of extract can be produced from 45 kg of ginger rhizome).
- composition for improving and/or maintaining ocular blood flow of the present invention is also suitably used for improving conditions, symptoms, and diseases related to ocular blood flow.
- examples Tet Examples
- ocular blood flow reduction model rats ocular blood flow increases.
- the present invention can also be used to maintain and promote the health of the vascular tissue in the eye.
- the ophthalmic artery enters the optic nerve at the optic disc, and the central retinal artery and posterior ciliary artery deliver blood that nourishes the retina.
- the ophthalmic artery branches into the short posterior ciliary artery, which receives blood flow at the optic nerve head and reaches the choroidal artery, which delivers blood that nourishes the outer layer of the retina.
- the present invention provides anti-aging and improved health of the entire eye, including the eye tissue without vascular invasion, by increasing blood flow in the vascular tissue of the eye. and/or can be maintained.
- the present invention can be applied to the eye. By increasing the blood flow rate of the vascular tissue, it is possible to improve, suppress the appearance or expansion (suppress the progression) of these conditions.
- the present invention makes it possible to actively deliver blood components, including to the eye tissue without blood vessel invasion.
- the circulation of tissue fluid also improves (improvement of tissue blood flow).
- tissue blood flow tissue blood flow
- tissue blood flow tissue blood flow
- major retinal arteries such as the central retinal artery radiating from the optic disc were observed. It has been confirmed that not only vascular blood flow is improved, but also the circulation of capillaries and tissue fluid (tissue blood flow), and that overall blood flow in the eye area is improved.
- the present invention is capable of increasing ocular blood flow, ocular tissue blood flow, and total ocular blood flow, thereby treating and/or preventing ocular circulation disorders. It can be used for any purpose.
- ocular circulation disorders examples include glaucoma, retinal vein occlusion, retinal artery occlusion, ocular ischemic syndrome, internal carotid artery occlusion, renal retinopathy, transient amaurosis, and age-related macular degeneration. It will be done. Although not limited to, glaucoma, age-related macular degeneration, or retinal vein occlusion are preferred as the ocular circulation disorder from the viewpoint of increasing ocular blood flow, ocular tissue blood flow, and overall blood flow in the eye. .
- the present invention has been confirmed to increase blood flow in the vascular tissue of the eye.
- Those who are concerned about the circulation of blood (blood) those who want to improve the function of the optic nerve and muscles around the eye by improving the circulation of blood (blood) in the eye area, those who are concerned about the function of the optic nerve and muscles around the eye.
- People who want to deliver blood to their eyes by improving blood circulation in the eye area people who want to support eye health, people who are concerned about lack of visual field, people who are concerned about narrowing of their visual field. It can also be suitably used for people who have difficulty seeing.
- the present invention can be enclosed in a package in which these conditions and uses are clearly stated or evoked through words, illustrations, etc., and can be transferred to a consumer.
- the eye region is lined with microscopic blood vessels, and microcirculation (microcirculation) is responsible for nourishing each tissue. Therefore, in one embodiment, the present invention can be suitably used for those who want to improve the microcirculation of the eye and those who are concerned about the microcirculation of the eye.
- prevention refers to preventing or delaying the occurrence of a specific condition or disease, or reducing the risk of the occurrence of a specific condition or disease.
- improvement refers to alleviation or improvement of a specific condition or disease, prevention or delay of deterioration of an abnormal condition, or prevention, delay, or reversal of the progression of a specific condition or disease.
- the composition of the present invention can be added to or mixed with foods, drinks, medicines, feeds, and pet foods. Alternatively, it can be used as is as a drink or food. Or, the functions include improving ocular blood flow, protecting the retina, anti-aging of the eye, maintaining the health of the eye, improving vision, maintaining homeostasis of vascular tissue, reducing or preventing the risk of ocular circulation disorders, etc. It can be used explicitly or implicitly as a food or drink, that is, a health food, a food with functional claims, a food for the sick, or a food for specified health uses. Further, even if the above-mentioned functionality is not explicitly stated or implied, it can be used as a so-called doctor's supplement provided by a doctor at a hospital and/or clinic.
- health foods, foods with functional claims, foods for the sick, and foods for specified health uses include solid preparations (tablets, orally disintegrating tablets, granules, fine granules, powders, capsules, chewable tablets, and candies). It can be used in various formulations such as liquid preparations (syrups, suspensions), liquid foods, etc.
- Foods in the form of formulations can be produced in the same manner as known pharmaceutical preparations, and are produced by mixing the active ingredient and a food-acceptable carrier, such as an appropriate excipient, using conventional means. be able to.
- the formulation form is not limited, it is preferably an orally disintegrating tablet, a chewable tablet, a candy, a granule, a powder, or a liquid from the viewpoint of achieving the effects of the present invention.
- tablets can be prepared by compression molding a mixture of a powdered active ingredient and a pharmaceutically acceptable carrier component (such as an excipient), and confectionery tablets such as candies can be prepared by molding. It may also be prepared by injection. Tablets may be coated with sugar to form sugar-coated tablets. Furthermore, the tablet may be a single-layer tablet or a laminated tablet such as a two-layer tablet.
- a pharmaceutically acceptable carrier component such as an excipient
- confectionery tablets such as candies can be prepared by molding. It may also be prepared by injection. Tablets may be coated with sugar to form sugar-coated tablets.
- the tablet may be a single-layer tablet or a laminated tablet such as a two-layer tablet.
- Powder granules such as granules can be produced using various granulation methods (extrusion granulation, pulverization granulation, dry compaction granulation, fluidized bed granulation, rolling granulation, high-speed agitation granulation, etc.) Tablets can be prepared by appropriately combining the above-mentioned granulation method, tableting method (wet tableting method, direct tableting method), etc.
- Capsules can be prepared by filling powders (powders, granules, etc.) into capsules (soft or hard capsules) by a conventional method.
- Liquid preparations can be prepared by dissolving or dispersing each component in an aqueous medium (purified water, ethanol-containing purified water, etc.) as a carrier component, filtering or sterilizing it if necessary, filling it into a designated container, and sterilizing it.
- aqueous medium purified water, ethanol-containing purified water, etc.
- a preferred dosage form of the solid preparation of the present invention is a capsule or a tablet, and more preferably a soft capsule.
- Soft capsules have a smooth surface and are easy to swallow, making them preferred by users.
- Examples of common methods for producing soft capsules include a flat plate method, a rotary method, and a seamless method.
- a sheet-like capsule film sandwiches the flowing filling contents and forms a capsule shape along the holes of a rotating cylindrical mold.
- the seamless method dropping method
- the capsule coating composition and the contents are simultaneously discharged from multiple concentric nozzles, forming a seamless capsule shape.
- the base material for the film of the soft capsule is not particularly limited, but starch, pullulan, cellulose, polyvinyl alcohol, gelatin, succinated gelatin, etc. can be used, and starch, gelatin, and succinated gelatin are preferred, and gelatin, succinated gelatin, etc. Further preferred is gelatin. These may be used alone or in combination of two or more.
- the composition of the present invention can be produced as beverages, liquid drinks such as diet drinks, semi-solid foods such as puddings and yogurt, noodles, confectionery, spreads, and the like.
- various food additives may be added.
- food additives include antioxidants, pigments, fragrances, seasonings, sweeteners, acidulants, pH adjusters, quality stabilizers, preservatives, and the like.
- composition of the present invention is prepared as a pharmaceutical composition
- it is prepared as a preparation containing the active ingredient, ginger and/or an extract thereof, and preferably a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier generally refers to an inert, non-toxic, solid or liquid filler, diluent, or encapsulating material that does not react with the active ingredient, such as water. , ethanol, polyols, appropriate mixtures thereof, solvents or dispersion media such as vegetable oils, and the like.
- the pharmaceutical composition is administered orally, parenterally, for example, into the oral cavity, into the gastrointestinal tract, or into the nasal cavity.
- Orally administered preparations include solid preparations (tablets, orally disintegrating tablets, granules, fine granules, powders, capsules, chewable tablets, lozenges, etc.) and liquid preparations (syrups, suspensions, inhalants), etc. can be mentioned.
- parenteral preparations include eye drops, drops, nasal drops, and injections.
- the formulation form is not limited, it is preferably an orally disintegrating tablet, a chewable tablet, a candy, a granule, a powder, or a liquid from the viewpoint of achieving the effects of the present invention.
- the pharmaceutical composition may further contain additives commonly used in the pharmaceutical field.
- additives include, for example, excipients, binders, disintegrants, lubricants, antioxidants, coloring agents, and flavoring agents, which can be used as appropriate.
- excipients for example, excipients, binders, disintegrants, lubricants, antioxidants, coloring agents, and flavoring agents, which can be used as appropriate.
- binders for example, excipients, binders, disintegrants, lubricants, antioxidants, coloring agents, and flavoring agents, which can be used as appropriate.
- coloring agents include, for example, binders, disintegrants, lubricants, antioxidants, coloring agents, and flavoring agents, which can be used as appropriate.
- coloring agents for example, a known ethanol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbito
- the pharmaceutical composition can be applied in the form of an oral composition, an internal composition, or the like.
- the pharmaceutical compositions may also be used therapeutically or non-therapeutically.
- the daily oral intake or dosage of ginger and/or its extract for adults depends on the condition of the individual, body weight, sex, age, activity of the material, route of intake or administration, schedule of intake or administration, formulation form, and other factors. It can be determined as appropriate depending on the following factors.
- the daily oral intake or dosage of ginger and/or its extract for adults is, for example, preferably 0.01 mg/kg body weight/day or more, more preferably 0.02 mg/kg body weight/day or more, and 0.01 mg/kg body weight/day or more, for example. More preferably .05 mg/kg body weight/day or more, particularly preferably 0.1 mg/kg body weight/day or more.
- the daily oral intake or dosage of ginger and/or its extract for adults is, for example, preferably 10 mg/kg body weight/day or less, more preferably 5 mg/kg body weight/day or less, and 2 mg/kg body weight/day. More preferably, the amount is less than 1 mg/kg body weight/day, particularly preferably less than 1 mg/kg body weight/day.
- the daily oral intake or dosage of ginger and/or its extract for adults is, for example, preferably 0.01 to 10 mg/kg body weight/day, more preferably 0.02 to 5 mg/kg body weight/day. , 0.05 to 2 mg/kg body weight/day is more preferred, and 0.1 to 1 mg/kg body weight/day is particularly preferred.
- the content of ginger and/or its extract can be set to the above-mentioned intake or administration amount.
- the daily oral intake or dosage of ginger extract for adults is, for example, preferably 0.5 mg/day or more, more preferably 1 mg/day or more, and 3 mg/day or more. More preferably, 5 mg/day or more is particularly preferred, and 10 mg/day or more is most preferred.
- the daily oral intake or dosage of ginger extract for adults is, for example, preferably 500 mg/day or less, more preferably 200 mg/day or less, even more preferably 100 mg/day or less, particularly preferably 50 mg/day or less. .
- the daily oral intake or dosage of ginger extract for adults is, for example, preferably 0.5 to 500 mg/day, more preferably 1 to 200 mg/day, even more preferably 3 to 100 mg/day. , 5 to 50 mg/day or less is particularly preferred.
- the daily oral intake or dosage of ginger for adults is, for example, preferably 20 mg/day or more, more preferably 40 mg/day or more, even more preferably 120 mg/day or more, and 200 mg/day or more. /day or more is particularly preferred, and 400 mg/day or more is most preferred.
- the daily oral intake or dosage of ginger for adults is, for example, preferably 5000 mg/day or less, more preferably 3000 mg/day or less, even more preferably 1000 mg/day or less, and particularly preferably 800 mg/day or less.
- the oral intake or dosage of ginger is, for example, preferably 20 to 5000 mg/day or less, more preferably 40 to 3000 mg/day, even more preferably 120 to 1000 mg/day, particularly 200 to 800 mg/day. preferable.
- the effective dose for animals is converted to the human dose as the dose per kg of body weight, and the dose is 1/60 or less.
- This method can be used. That is, if the effective dose for animals is X mg/kg, the dose for humans (mg/day) can be calculated as follows: X (mg) x body weight (kg)/60-600.
- the daily oral intake or dosage of ginger and/or its extract for adults is, for example, 1 mg/day or more, 2 mg/day or more, 3 mg/day or more, 4 mg/day or more, 5 mg/day or more, 6 mg/day or more, 7 mg/day or more, 8 mg/day or more, 9 mg/day or more, 10 mg/day or more, and 1000 mg/day or less, 900 mg/day or less, 800 mg/day or less, 700 mg/day or less, 600 mg/day or less, 500 mg/day or less, 400 mg/day or less, 300 mg/day or less, 200 mg/day or less, 150 mg/day or less, 100 mg/day or less, 75 mg/day or less, 50 mg/day or less, It can also be 30 mg/day or less, 20 mg/day or less, or 10 mg/day or less.
- oral intake or dosage per day for adults is 1 to 6 capsules, 1 to 4 capsules, 1 to 3 capsules, or 1 to 2 capsules depending on the dosage form. May be taken separately.
- composition of the present invention is divided into once to several times a day, usually taken or administered 1 to 6 times a day, 1 to 3 times a day, 1 to 2 times a day, or at any period and interval. However, once a day is preferred.
- the present invention may also have the following aspects.
- a composition for improving and/or maintaining ocular blood flow containing ginger and/or an extract thereof;
- a composition for maintaining the health of vascular tissue in the eye containing ginger and/or an extract thereof;
- An anti-aging composition for the eye region containing ginger and/or an extract thereof;
- a composition for the treatment and/or prevention of ocular circulation disorders containing ginger and/or an extract thereof;
- Compositions containing ginger and/or extracts thereof for use in improving and/or maintaining ocular blood flow A composition containing ginger and/or an extract thereof for use in maintaining the health of vascular tissue of the eye;
- Compositions containing ginger and/or extracts thereof for use in anti-aging of the eye Compositions containing ginger and/or extracts thereof for use in improving and/or maintaining ocular
- the above composition which is a pharmaceutical product or a food or drink product;
- the above composition, use, or method, wherein the dosage form is an orally disintegrating tablet, a chewable tablet, a lozenge, a granule, a powder, or a liquid;
- the above composition, use, or method, wherein the ginger is red ginger;
- the above composition, use, or method, wherein the ginger and/or extract thereof is red ginger and/or an extract thereof;
- the above composition, use, or method, wherein the ginger part comprises a rhizome;
- the above composition, use, or method, wherein the extraction solvent in the ginger extract is aqueous ethanol;
- the above composition, use, or method, wherein the total content of [6]-gingerol and [6]-shogaol in red ginger is 3.0% by mass or more;
- the above composition, use, or method, wherein the total content of [6]-gingerol and [6]-shogaol in red ginger is
- the present invention will be specifically explained with reference to Examples, but the present invention is not limited to the following Examples.
- the amount of extract shown in the Examples is the amount calculated in terms of dry solid content and including excipients and the like.
- red ginger extract powder red ginger extract-P, manufactured by Oryza Yuka Co., Ltd., indicated as "O-2" in the figure, the same hereinafter
- O-2 red ginger extract powder
- Figure 1 shows the measurement results of the baseline ocular blood flow and the ocular blood flow after ingestion of the test sample.
- eight rats were used in each administration group, and statistical processing was performed using the Holm-Sidak test.
- AveALL (V) in the figure indicates the blood flow rate (MBR average value, the same applies hereinafter) in the blood vessel region.
- control group The same as the above oral administration group except that red ginger extract powder was not administered. Specifically, healthy rats (Brown Norway, male, 8-12 weeks old, manufactured by SLC) were anesthetized, and 10 minutes later, 2.5 pmol of endothelin-1 was administered intravitreally. 10 and 20 minutes after endothelin-1 administration, ocular blood flow was determined by laser speckle flowgraphy (AveALL (A): blood flow in the entire region, AveALL (V): blood flow in the vascular region, AveALL (T): tissue region blood flow rate), pulse rate, mean blood pressure, and intraocular pressure were measured.
- A blood flow in the entire region
- AveALL (V) blood flow in the vascular region
- AveALL (T) tissue region blood flow rate
- pulse rate mean blood pressure
- intraocular pressure intraocular pressure
- the posterior segment blood flow map 10 minutes after endothelin-1 administration is shown in FIG. 4, and the graphs after analysis are shown in FIGS. 5 to 7. Statistical processing was performed using the student-t test. Further, the posterior ocular blood flow map 20 minutes after endothelin-1 administration is shown in FIG. 8, and the graphs after analysis are shown in FIGS. 9 to 11. Statistical processing was performed using the student-t test.
- E1 endothelin-1
- endothelin-1 (ET1) models glaucoma, which reduces ocular blood flow. Therefore, it was suggested that, although not limited to, ingesting (administering) ginger is suitable for treating and/or preventing glaucoma among ocular circulation disorders.
- Test Example 4 Ocular blood flow evaluation test after cold load in humans
- heat radiation from skin blood vessels is suppressed, causing vasoconstriction and a decrease in blood flow.
- blood flow recovers over time. These phenomena are said to occur with regard to ocular blood flow in humans who are highly sensitive to cold stress.
- Test Examples 2 and 3 by using laser speckle flowgraphy, it becomes possible to quantitatively evaluate changes in ocular blood flow.
- a substance that can shorten the blood flow recovery period after a cold load will contribute to improving and/or maintaining ocular blood flow, maintain the health of the vascular tissue in the eye, anti-aging the eye, visual field narrowing, and visual field loss.
- red ginger extract-P manufactured by Oryza Yuka Co., Ltd.
- Healthy subjects were brought into the test room and seated in a chair in the test room at a room temperature of 24 to 25°C, allowed to rest for 30 minutes and acclimatized to the test environment, and then allowed to ingest or not ingest the test food. The subjects were then seated in a chair in a test room at a room temperature of 24-25°C and allowed to rest for 30 minutes. Then, as in Test Examples 2 and 3, the ocular blood flow before loading was measured using laser speckle flowgraphy (LSFG-NAVI, manufactured by Softcare Co., Ltd.) and the attached analysis application (LSFG analyzer). Blood flow values (initial values) before cold loading were obtained.
- LSFG-NAVI laser speckle flowgraphy
- LSFG analyzer attached analysis application
- the subjects were allowed to ingest the test food 30 minutes before the cold load or were not ingested, and were allowed to sit on a chair in a test room at a room temperature of 24 to 25°C and rest for 30 minutes.
- the content of the red ginger extract itself (without excipients) in the test food was approximately 10 mg/day as a dry solid content.
- a nitrile glove was put on the right hand, and the right wrist was immersed in warm water at 40°C for 2 minutes. Thereafter, the right wrist was immersed in cold water at 4° C. for 1 minute to perform a cold load. After the cold load, moisture was immediately wiped off with a paper towel or the like, and fundus blood flow was measured 4 and 6 minutes after the cold load. A similar test was conducted on the same subjects under crossover conditions with a sufficient washout period.
- the fundus blood flow measurement in this test example measures the blood flow rate (MBR average value) in the tissue region of the optic nerve head.
- MBR average value blood flow rate
- subjects whose optic disc temperature decreased were evaluated as responders (nine subjects in this study).
- the results are shown in FIG.
- the upper line graph is the test food group, and the lower line graph is the non-ingestion group.
- the vertical axis indicates the average value of the amount of change in MBR.
- ginger red ginger extract
- the ocular blood flow could be increased and the blood flow recovery period could be shortened after a cold load, compared to the control group. Therefore, ginger (red ginger extract) contributes to improving and/or maintaining ocular blood flow, maintains the health of the vascular tissue in the eye, anti-aging the eye, and prevents visual field narrowing, visual field defects, scotoma, etc. It is expected to be effective in the treatment and/or prevention of various ocular circulation disorders.
- the red ginger extract (red ginger extract-P, manufactured by Oryza Yuka Co., Ltd.) used in the above examples was extracted from the rhizome with aqueous ethanol, and the total content of [6]-gingerol and [6]-shogaol was 6. .0% by mass or more, tannins in an amount of 1.5% by mass or more, and an equal amount of cyclodextrin mixed as an excipient.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Le but de la présente invention est de fournir une composition qui atténue les affections liées au débit sanguin oculaire, par évaluation des effets sur le débit sanguin oculaire. L'invention concerne une composition destinée à améliorer et/ou maintenir le débit sanguin oculaire, ladite composition contenant du Zingiber officinale et/ou un extrait de celui-ci. L'invention concerne également une composition destinée à préserver la santé des tissus vasculaires dans la région oculaire, une composition anti-vieillissement de la région oculaire, une composition destinée à améliorer et/ou préserver la santé de la région oculaire, à atténuer le rétrécissement du champ visuel, les défauts du champ visuel ou l'apparition ou l'extension d'une tache sombre, ainsi qu'une composition destinée à traiter et/ou prévenir des troubles de la circulation oculaire, chaque composition contenant l'ingrédient susmentionné.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022-117229 | 2022-07-22 | ||
JP2022117229 | 2022-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024019171A1 true WO2024019171A1 (fr) | 2024-01-25 |
Family
ID=89617947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2023/026874 WO2024019171A1 (fr) | 2022-07-22 | 2023-07-21 | Composition destinée à améliorer le débit sanguin oculaire |
Country Status (2)
Country | Link |
---|---|
TW (1) | TW202408561A (fr) |
WO (1) | WO2024019171A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06183959A (ja) * | 1992-12-17 | 1994-07-05 | Pola Chem Ind Inc | 血行促進剤 |
JP2007051090A (ja) * | 2005-08-18 | 2007-03-01 | Pharma Foods International Co Ltd | 卵白ペプチドを有効成分として含有する血流改善剤 |
JP2010100561A (ja) * | 2008-10-23 | 2010-05-06 | Mitsukan Group Honsha:Kk | 毛様体筋緊張緩和剤 |
JP2018188438A (ja) * | 2017-05-10 | 2018-11-29 | ロート製薬株式会社 | 後眼部疾患の予防、改善、又は治療用組成物 |
JP2019055917A (ja) * | 2017-09-20 | 2019-04-11 | 御木本製薬株式会社 | エンドセリン−1抑制剤 |
-
2023
- 2023-07-21 TW TW112127428A patent/TW202408561A/zh unknown
- 2023-07-21 WO PCT/JP2023/026874 patent/WO2024019171A1/fr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06183959A (ja) * | 1992-12-17 | 1994-07-05 | Pola Chem Ind Inc | 血行促進剤 |
JP2007051090A (ja) * | 2005-08-18 | 2007-03-01 | Pharma Foods International Co Ltd | 卵白ペプチドを有効成分として含有する血流改善剤 |
JP2010100561A (ja) * | 2008-10-23 | 2010-05-06 | Mitsukan Group Honsha:Kk | 毛様体筋緊張緩和剤 |
JP2018188438A (ja) * | 2017-05-10 | 2018-11-29 | ロート製薬株式会社 | 後眼部疾患の予防、改善、又は治療用組成物 |
JP2019055917A (ja) * | 2017-09-20 | 2019-04-11 | 御木本製薬株式会社 | エンドセリン−1抑制剤 |
Non-Patent Citations (1)
Title |
---|
TSUDA, TAKANORI; OSAWA, TOSHIHIKO : "Anthocyanin", JOURNAL OF THE EYE, MEDICAL AOI PUBLICATION, JP, vol. 25, no. 10, 1 January 2008 (2008-01-01), JP , pages 1393 - 1395, XP009552733, ISSN: 0910-1810 * |
Also Published As
Publication number | Publication date |
---|---|
TW202408561A (zh) | 2024-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6936932B2 (ja) | フラボノイド組成物及び使用方法 | |
US20070036873A1 (en) | Method of treatment or management of stress | |
US7932288B2 (en) | Composition for relieving subjective symptoms of fatigue | |
US20180104299A1 (en) | Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiation agent for the treatment of obesity | |
CN101903033A (zh) | 由银杏叶制成的提取物的用途 | |
JP2008528483A (ja) | 三七根、熟地黄、五加皮の混合生薬材抽出物及びそれを有効成分とする関節炎予防及び治療用組成物 | |
JP2011522844A (ja) | 血糖レベルを低下させる組成物及びその用途 | |
JP4873904B2 (ja) | 眼血管血流障害改善剤 | |
KR101987418B1 (ko) | 혼합 생약 추출물을 유효성분으로 함유하는 뇌신경 보호용 조성물 | |
WO2020179747A1 (fr) | Composition inhibitrice d'hif | |
KR102348044B1 (ko) | 번아웃증후군의 예방, 개선 또는 치료용 조성물 | |
WO2024019171A1 (fr) | Composition destinée à améliorer le débit sanguin oculaire | |
KR102009966B1 (ko) | 굴피나무 추출물을 유효성분으로 함유하는 뇌졸중 치료, 개선 또는 예방용 조성물 | |
TWI437998B (zh) | 大葉冬青提取物之用途 | |
KR101660834B1 (ko) | 지페노사이드 75의 항당뇨 효과 | |
JP7435442B2 (ja) | 血管内皮機能改善用又は末梢血管の血流改善用組成物 | |
KR102245027B1 (ko) | 상추 및 황금 추출물을 유효성분으로 함유하는 수면 장애 개선용 조성물 | |
WO2019168185A1 (fr) | Composition alimentaire permettant d'empêcher et/ou de réduire le risque d'anomalies dans le segment postérieur de l'œil | |
JP4669077B1 (ja) | アスパラガス擬葉を有効成分とする自律神経調整剤 | |
KR20040092232A (ko) | 성기능 개선용 홍삼복합물, 이의 제조방법 및 이의 용도 | |
JP3345650B2 (ja) | 高血圧抑制剤 | |
JP2020015679A (ja) | 下部尿路症状改善用組成物 | |
WO2021117547A1 (fr) | Aliment pour prévenir ou améliorer les symptômes du bas appareil urinaire | |
KR20220076720A (ko) | 미병의 예방 또는 개선용 식품 조성물 | |
JP2024017059A (ja) | 感冒症状抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23843094 Country of ref document: EP Kind code of ref document: A1 |